Research, Clinical Trials, Drug Resistance and Safety for Cancer Immunotherapy in Head and Neck Cancers and Brain Tumors

Know about the book -

Research, Clinical Trials, Drug Resistance and Safety for Cancer Immunotherapy in Head and Neck Cancers and Brain Tumors is written by Ling Zhang and published by Frontiers Media SA. It's available with International Standard Book Number or ISBN identification 2832509584 (ISBN 10) and 9782832509586 (ISBN 13).

Head and neck cancers (HNCs) and brain tumors continue to be fatal diseases in most countries of the world. In the past decade, cancer immunotherapy has emerged as a promising therapeutic strategy and achieved unprecedented bench-to-bedside clinical success in the field of oncology. Different from traditional surgery, chemotherapy, and radiotherapy, the current cancer immunotherapy aims to recover or enhance the immune system of a patient, to recognize and eliminate cancerous cells from the primary tumor and metastases. Numerous immunotherapy strategies, in particular immune checkpoint inhibitors, adoptive cellular therapies, and cancer vaccines, are under pre-clinical investigations or in ongoing clinical trials in a range of cancer types. Among them, novel drugs have continued to be approved by the FDA, which has revolutionized the current cancer treatment by prolonging the survival time of the patients, especially in advanced unresectable tumors. However, not all patients achieve complete responses to immunotherapy due to de novo or acquired resistance. Also, immunotherapy-related adverse events are common, although it has a better safety profile than the traditional treatments. It has limited the application and efficacy of cancer immunotherapy in tumors, including the HNCs and brain tumors, and highlights the need for new strategies.